Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer

File Description SizeFormat 
1000 Focal HIFU BJUI 13.7.18.docxFile embargoed until 18 March 2020112.2 kBMicrosoft Word    Request a copy
Table 1_Final.docxFile embargoed until 18 March 202022.35 kBMicrosoft Word    Request a copy
Table 2_Final.docxFile embargoed until 18 March 202015.5 kBMicrosoft Word    Request a copy
Table 3_Final.docxFile embargoed until 18 March 202015.06 kBMicrosoft Word    Request a copy
Title: Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer
Authors: Stabile, A
Orczyk, C
Hosking-Jervis, F
Giganti, F
Arya, M
Hindley, RG
Dickinson, L
Allen, C
Punwani, S
Jameson, C
Freeman, A
McCartan, N
Montorsi, F
Briganti, A
Ahmed, HU
Emberton, M
Moore, CM
Item Type: Journal Article
Abstract: OBJECTIVE: To report medium-term oncological outcomes in patients receiving primary focal treatment with HIFU for PCa. PATIENTS AND METHODS: Consecutive men treated by means of primary focal HIFU for PCa at two centres by 6 treating clinicians were assessed. Patients were submitted to either a focal ablation or hemiablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium-term oncological outcomes defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU. The secondary objective was to evaluate the changes in pathological features among patients treated by means of focal HIFU over time. We also assessed the relationship between year of surgery and 5-years retreatment probability. RESULTS: One thousand and thirty-two men treated between November 2005 and October 2017 were assessed. The median age was 65 yrs and median prostate-specific antigen was 7 ng/ml. The majority of patients had Gleason score of 3+4 or above (80.3%). Median follow-up was 36 months (IQR: 14-64). The overall survival at 24, 60 and 96 months was 99%, 97% and 97%, respectively. Freedom from biopsy failure, defined as absence of Gleason 3+ 4 disease, was 84%, 64% and 54% at 24, 60 and 96 months. Freedom from any further treatment was 85, 59 and 46% at 24, 60 and 96 months, respectively. Roughly 70% of patients retreated received a 2nd focal treatment. Freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months. During the study period we have seen an increase in the proportion of patients undergoing focal HIFU with Gleason 3+4 disease and with T2 mpMRI staged disease. Finally, we report a reduction over time in the proportion of men undergoing re-treatment within 5-years of first treatment. CONCLUSIONS: Focal HIFU for PCa is a feasible therapeutic strategy with acceptable survival and oncological results, with a reduction in the 5 year retreatment rates over the last decade. Re-do focal treatment is a feasible technique whose functional and oncological outcomes have still to be evaluated.
Issue Date: Sep-2019
Date of Acceptance: 1-Feb-2019
URI: http://hdl.handle.net/10044/1/68144
DOI: https://doi.org/10.1111/bju.14710
ISSN: 1464-4096
Publisher: Wiley
Start Page: 431
End Page: 440
Journal / Book Title: BJU International
Volume: 124
Issue: 3
Copyright Statement: © 2019 The Authors. This is the accepted version of the following article: Stabile, A. , Orczyk, C. , Hosking‐Jervis, F. , Giganti, F. , Arya, M. , Hindley, R. G., Dickinson, L. , Allen, C. , Punwani, S. , Jameson, C. , Freeman, A. , McCartan, N. , Montorsi, F. , Briganti, A. , Ahmed, H. U., Emberton, M. and Moore, C. M. (2019), Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer. BJU Int., which has been published in final form at https://dx.doi.org/10.1111/bju.14710
Sponsor/Funder: Wellcome Trust
University College London Hospitals Charity
Funder's Grant Number: 204998/Z/16/Z
1348
Keywords: Science & Technology
Life Sciences & Biomedicine
Urology & Nephrology
focal therapy
high-intensity focused ultrasonography
#PCSM
#ProstateCancer
#HIFU
BEAM RADIOTHERAPY
THERAPY
ULTRASOUND
Science & Technology
Life Sciences & Biomedicine
Urology & Nephrology
#HIFU
#PCSM
#ProstateCancer
focal therapy
high-intensity focused ultrasonography
HIFU
focal therapy
high intensity focused ultrasound
outcome
prostate cancer
therapy
Urology & Nephrology
1103 Clinical Sciences
Publication Status: Published
Conference Place: England
Embargo Date: 2020-03-18
Online Publication Date: 2019-03-18
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons